Evacetrapib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia
Trial Timeline
May 1, 2014 → Dec 1, 2015
NCT ID
NCT02168803About Evacetrapib
Evacetrapib is a phase 1 stage product being developed by Eli Lilly for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02168803. Target conditions include Dyslipidemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02497391 | Phase 1 | Completed |
| NCT02226653 | Phase 1 | Completed |
| NCT02168803 | Phase 1 | Completed |
| NCT01903434 | Phase 1 | Completed |
| NCT01825889 | Phase 1 | Completed |
| NCT01836185 | Phase 1 | Completed |
| NCT01810432 | Phase 1 | Completed |
Competing Products
20 competing products in Dyslipidemia